Our work suggests that cyclin E may be a driver of this unique biology in IBC, and therefore early targeting of this pathway may be beneficial, especially in patients with demonstrated intrinsic resistance to chemotherapy. The gene discussed is CCNE1; the disease is inflammatory breast carcinoma.